X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sorafenib (94) 94
index medicus (79) 79
humans (71) 71
niacinamide - analogs & derivatives (57) 57
pharmacology & pharmacy (44) 44
oncology (32) 32
male (29) 29
animals (28) 28
cancer (27) 27
female (27) 27
antineoplastic agents (23) 23
antineoplastic agents - therapeutic use (23) 23
antimitotic agents (22) 22
pharmacokinetics (22) 22
phenylurea compounds (22) 22
antineoplastic agents - pharmacokinetics (20) 20
metabolites (19) 19
middle aged (19) 19
protein kinase inhibitors - therapeutic use (19) 19
analysis (18) 18
pharmacology/toxicology (18) 18
phenylurea compounds - administration & dosage (17) 17
phenylurea compounds - pharmacokinetics (17) 17
renal-cell carcinoma (17) 17
sunitinib (17) 17
carcinoma, hepatocellular - drug therapy (16) 16
hepatocellular carcinoma (16) 16
niacinamide - administration & dosage (16) 16
adult (15) 15
aged (15) 15
antineoplastic agents - adverse effects (15) 15
article (15) 15
liver neoplasms - drug therapy (15) 15
medicine & public health (15) 15
pyridines - pharmacokinetics (15) 15
pyridines - therapeutic use (15) 15
antitumor-activity (14) 14
multikinase inhibitor (14) 14
niacinamide - pharmacokinetics (14) 14
phenylurea compounds - therapeutic use (14) 14
protein kinase inhibitors - pharmacokinetics (14) 14
antineoplastic agents - administration & dosage (13) 13
protein kinase inhibitors - adverse effects (13) 13
refractory solid tumors (13) 13
antineoplastic agents - pharmacology (12) 12
benzenesulfonates - therapeutic use (12) 12
mice (12) 12
niacinamide - therapeutic use (12) 12
phase-i (12) 12
protein kinase inhibitors - administration & dosage (12) 12
protein kinase inhibitors - pharmacology (12) 12
pyridines - adverse effects (12) 12
dose-response relationship, drug (11) 11
hepatocellular-carcinoma (11) 11
raf kinase (11) 11
advanced hepatocellular-carcinoma (10) 10
antineoplastic agents - blood (10) 10
cancer research (10) 10
endothelial growth-factor (10) 10
liver cancer (10) 10
mass spectrometry (10) 10
neoplasms (10) 10
safety (10) 10
tyrosine kinase inhibitor (10) 10
benzenesulfonates - adverse effects (9) 9
benzenesulfonates - pharmacokinetics (9) 9
carcinoma, renal cell - drug therapy (9) 9
chemistry, analytical (9) 9
kidney neoplasms - drug therapy (9) 9
metabolism (9) 9
phenylurea compounds - adverse effects (9) 9
phenylurea compounds - blood (9) 9
pyridines - administration & dosage (9) 9
pyridines - blood (9) 9
tumors (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
care and treatment (8) 8
chemotherapy (8) 8
disease-free survival (8) 8
drug interactions (8) 8
drug therapy (8) 8
factor receptor inhibitor (8) 8
in-vitro (8) 8
management (8) 8
neoplasms - drug therapy (8) 8
phenylurea compounds - pharmacology (8) 8
regorafenib (8) 8
reproducibility of results (8) 8
treatment outcome (8) 8
tyrosine (8) 8
tyrosine kinase inhibitors (8) 8
aged, 80 and over (7) 7
angiogenesis (7) 7
apoptosis (7) 7
bay-43-9006 (7) 7
biochemical research methods (7) 7
biochemistry & molecular biology (7) 7
cell proliferation - drug effects (7) 7
double-blind (7) 7
hematology (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The AAPS Journal, ISSN 1550-7416, 3/2019, Volume 21, Issue 2, pp. 1 - 11
Journal Article
The AAPS Journal, ISSN 1550-7416, 11/2019, Volume 21, Issue 6, pp. 1 - 10
The multikinase inhibitor sorafenib (SOR) is used to treat patients with hepatocellular and renal carcinomas. SOR undergoes CYP-mediated biotransformation to a... 
Biochemistry, general | Biotechnology | dextromethorphan O-demethylation | Biomedicine | molecular docking | CYP2D6 inhibition | sorafenib | Pharmacy | metabolite inhibition | Pharmacology/Toxicology | sorafenib N -oxide | Medical colleges | Pharmacogenetics | Metabolites | Comorbidity | Analysis | Cytochrome P-450 | Crystals | Drug therapy, Combination | Structure
Journal Article
The Tohoku Journal of Experimental Medicine, ISSN 0040-8727, 2014, Volume 233, Issue 2, pp. 103 - 112
Journal Article
The Tohoku Journal of Experimental Medicine, ISSN 0040-8727, 2015, Volume 237, Issue 3, pp. 173 - 182
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 03/2018, Volume 114, pp. 55 - 63
The tyrosine kinase inhibitors sorafenib and imatinib are important in the treatment of a range of cancers but adverse effects in some patients necessitate... 
Imatinib biotransformation | CYP2C8 | Sorafenib biotransformation | Hepatic cirrhosis | CYP3A4 | ADVANCED HEPATOCELLULAR-CARCINOMA | CYTOCHROME-P450 | RENAL-CELL CARCINOMA | N-OXIDE | PHASE-I TRIAL | INHIBITORY INTERACTIONS | PHARMACOLOGY & PHARMACY | REFRACTORY SOLID TUMORS | JAPANESE PATIENTS | GASTROINTESTINAL STROMAL TUMORS | DRUG-METABOLISM
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2015, Volume 38, Issue 11, pp. 1788 - 1793
The multikinase inhibitor sorafenib has been used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.... 
Journal Article
Xenobiotica, ISSN 0049-8254, 07/2016, Volume 46, Issue 7, pp. 651 - 658
1. The aim of this study was to investigate the potential drug-drug interaction of sorafenib mediated by P-glycoprotein (P-gp) and cytochrome P450 3A4... 
Caco-2 cells | P-gp | sorafenib | CYP450 | drug-drug interaction | oral absorption | HPLC-UV METHOD | HUMAN PLASMA | RESISTANCE PROTEIN ABCG2 | DASATINIB | COMBINATION | CANCER | N-OXIDE | NANOPARTICLES | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CARCINOMA
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 06/2018, Volume 32, Issue 6, pp. e4184 - n/a
Journal Article
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 01/2020, Volume 177, p. 112881
The present study was to investigate the degradation profile of sorafenib tosylate (SORA), a potent oral multi-kinase inhibitor under various stress conditions... 
Density functional theory | Isolation | QTOF/MS | NMR | Sorafenib tosylate
Journal Article
Journal Article
Best Practice & Research Clinical Gastroenterology, ISSN 1521-6918, 2006, Volume 20, Issue 2, pp. 315 - 326
There is still a substantial need for the development of new treatments for patients with pancreatic cancer. In this chapter, we will document that there is... 
sorafenib | epidermal growth factor receptor (EGFR) | thioredoxin | vascular endothelial growth factor (VEGF) | cetuximab | TNFerade | prostate specific cancer antigen (PSCA) | gastrin | thioredoxin reductase | vaccine | polo-like kinase | bevacizumab | hypoxia inducible factor alpha (HIF-1α) | gemcitabine | Gemcitabine | Epidermal growth factor receptor (EGFR) | Vascular endothelial growth factor (VEGF) | Vaccine | Thioredoxin | Thioredoxin reductase | Prostate specific cancer antigen (PSCA) | Bevacizumab | Sorafenib | Gastrin | Hypoxia inducible factor alpha (HIF-1α) | Polo-like kinase | Cetuximab | NUDE-MICE | hypoxia inducible factor alpha (HIF-I alpha) | MONOCLONAL-ANTIBODY | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | GEMCITABINE G | DOUBLE-BLIND | BEVACIZUMAB B | GASTROENTEROLOGY & HEPATOLOGY | DOSE-RATE | Niacinamide - analogs & derivatives | Gastrins - therapeutic use | Humans | Tegafur - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antibodies, Monoclonal, Humanized | Tumor Necrosis Factor-alpha - therapeutic use | Cancer Vaccines - therapeutic use | Cyclic N-Oxides - therapeutic use | Deoxycytidine - therapeutic use | Oxonic Acid - therapeutic use | Sulfonamides - therapeutic use | Adenoviridae - genetics | Deoxycytidine - analogs & derivatives | Drug Combinations | Pancreatic Neoplasms - therapy | Pyridines - therapeutic use | Monoclonal antibodies | Care and treatment | Drug therapy | Pancreatic cancer | Cancer
Journal Article